|
Volumn 35, Issue 7, 2003, Pages 2731-2732
|
Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIMETABOLITE;
AZATHIOPRINE;
CALCINEURIN INHIBITOR;
DACLIZUMAB;
GLOBULIN FRESENIUS THYMOCYTE ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PREDNISONE;
TACROLIMUS;
THYMOCYTE ANTIBODY;
UNCLASSIFIED DRUG;
ADULT;
BLOOD TRANSFUSION;
BOLUS INJECTION;
CLINICAL ARTICLE;
CONFERENCE PAPER;
CONTROLLED STUDY;
DIALYSIS;
DOPPLER FLOWMETRY;
DRUG SAFETY;
FEMALE;
FOLLOW UP;
GRAFT REJECTION;
GRAFT SURVIVAL;
HEMATOLOGIC DISEASE;
HIGH RISK PATIENT;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INTERMETHOD COMPARISON;
KIDNEY DONOR;
KIDNEY GRAFT;
KIDNEY TRANSPLANTATION;
MALE;
POSTOPERATIVE INFECTION;
PRIORITY JOURNAL;
RECIPIENT;
SIDE EFFECT;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
|
EID: 0242552420
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2003.08.043 Document Type: Conference Paper |
Times cited : (9)
|
References (16)
|